Biotia

We're #hiring a new Consulting Chief Financial Officer in United States. Apply today or share this post with your network.

Our?cofounders,?Dr. Niamh B. O'Hara, and?Dr. Christopher Mason, are at?#JPMorganHealthcareConference?in San Francisco this week! If you’re attending or nearby and would like to connect, don’t hesitate to reach out! They’d love to chat about innovation in?infectious disease diagnostics and biosecurity?and opportunities for collaboration. #JPM23 #HealthcareInnovation #Networking #HealthcareLeaders #JPMorgan

Niamh B. O'Hara, founder of Biotia, is using AI and genomics to revolutionize pathogen detections and healthcare. Through the Runway Startup Postdoc Program, Niamh turned her expertise into a company that improved health outcomes worldwide. Ready to turn your research into impact? Applications are open, learn more and apply today: https://bit.ly/3pPGicw #Entrepreneurship #TechInnovation #Runway #Cornell #CornellTech #BuildingVentures #EducatingLeaders #CreatingTechnologies #HealthTech | Cornell University

Great discussions happening at the Pasteur Network Avian Influenza Symposium in Phnom Penh! Dr. Heather Wells from Biotia is contributing to the conversation, presenting on our work developing solutions for avian influenza tracking and analysis. Collaboration is key in combating global health threats like this, and we're grateful to Dr. Erik Karlsson and the Pasteur Network for bringing together experts in the field. #AvianInfluenza #PublicHealth #PasteurNetwork

Excited to announce the beta release of our BIOTIA-DX Influenza Pipeline! This powerful tool provides H and N typing, H5 sub-clade analysis, and cleavage site detection from assembled genomes. It’s designed to give researchers detailed insights into influenza genomics, supporting surveillance and research efforts. We’re also working on exciting new features like recombination detection and pathogenicity scoring. If you’re interested in using the beta tool let us know!

???? World AMR Awareness Week: The Role of Diagnostics in the Fight Against Superbugs! ???? Fast, accurate diagnostics are game-changers in fighting infections and antimicrobial resistance. Molecular diagnostics and next-generation sequencing technologies help: ?? Pinpoint infections quickly – identifying the exact pathogen so patients get the right treatment faster. ?? Reduce unnecessary antibiotics – by targeting the specific cause, we avoid overusing broad-spectrum antibiotics. ?? Track resistance patterns – sequencing reveals emerging superbugs, guiding public health strategies. ?? Enable precision medicine – customizing treatment to match the unique infection profile. ?? The more we invest in cutting-edge diagnostics, the better we can protect lives AND preserve the effectiveness of antibiotics for future generations. ??? Let’s advocate for better access to advanced diagnostic tools worldwide! ???? I am proud working with Biotia to deliver precision medicine for infectious disease patients. #WorldAMRWeek #DiagnosticsSaveLives #StopSuperbugs #PrecisionMedicine #nextgenerationsequencing

Join Heather Wells, Biotia’s lead Bioinformatician, as she delves into the genomics of avian influenza and its potential to jump to humans. This presentation explores the genetic factors that drive cross-species transmission, with insights on how genomics can help predict and prevent future outbreaks. https://lnkd.in/grxRt2wd #h5n1 #GeoSeeq #avianinfluenza #birdflu

We’re thrilled to share that?Woman’s World?has featured Biotia in their latest article! Our groundbreaking work in the field of urinary infectious diseases, especially UTIs, is gaining well-deserved attention. We’ve just received approval for the?BIOTIA-ID Urine NGS Assay?as a?Laboratory Developed Test?— making it the?first genomics-based urine assay?to tackle UTIs and other urinary infections at a molecular level. This is a huge step forward in the fight against UTIs, offering faster, more accurate diagnoses and paving the way for better patient outcomes. #Biotia #InnovationInHealthcare #UTI #Genomics #Biotechnology #HealthcareInnovation #WomensHealth

Earlier this week, we were proud to announce that the New York State Department of Health has approved Biotia’s AI- and sequencing-based Urinary Tract Infection Test. This approval marks a significant step forward in transforming how UTIs are diagnosed—making the process faster, more precise, and more accessible. Catch the full coverage of this exciting news from GenomeWeb, who broke the story earlier this week. We’re excited about what this means for the future of healthcare and the impact it will have on patient outcomes. #Biotia #UTI #AI #Genomics #HealthTech #Diagnostics #Innovation #Healthcare

Biotia Gets First-Ever NY State Regulatory Approval for a Urine Infectious Disease Test Powered by Genomics and AI We are thrilled to share big news at Biotia! After?years of development and regulatory review, our BIOTIA-ID Urine NGS Assay has received New York State Department of Health regulatory approval! This is a major milestone for Biotia, as well as clinicians and patients seeking cutting-edge UTI tests which are more informative and accurate. This is especially important for patients suffering from recurrent or complicated UTIs. More about the test: - Unmatched Accuracy:?97% sensitivity and 99% specificity, far surpassing traditional methods. - AI-Powered:?Our advanced machine learning algorithms deliver rapid and precise results. - Comprehensive:?Identifies a broader range of pathogens, including those often missed by culture. Learn more about BIOTIA-ID and its potential to transform UTI diagnostics:?https://lnkd.in/emQGZy6w #UTI #diagnostics #womenshealth #precisionmedicine #AI #innovation #healthcare